Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody - PubMed (original) (raw)
. 1992 Feb 20;355(6362):728-30.
doi: 10.1038/355728a0.
Affiliations
- PMID: 1741059
- DOI: 10.1038/355728a0
Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
E A Emini et al. Nature. 1992.
Abstract
The acquired immunodeficiency syndrome (AIDS) is the late-stage clinical manifestation of long-term persistent infection with the human immunodeficiency virus type 1 (HIV-1). Immune responses directed against the virus and against virus-infected cells during the persistent infection fail to mediate resolution of the infection. As a result, a successful AIDS vaccine must elicit an immune state that will prevent the establishment of the persistent infection following introduction of the virus into the host. The third hypervariable (V3) domain of the HIV-1 gp120 envelope glycoprotein is a disulphide-linked closed loop of about 30 amino acids which binds and elicits anti-HIV-1 type-specific virus-neutralizing antibodies. The in vitro characteristics of anti-V3 domain antibody suggest that this antibody could by itself prevent HIV-1 infection in vivo, an idea supported by chimpanzee challenge studies in which protection against the HIV-1 persistent infection seemed to correlate with the presence of anti-V3 domain antibody. Here we directly demonstrate the protective efficacy of anti-V3 domain antibody in vivo and propose that this antibody is potentially useful as both a pre- and post-exposure prophylactic agent.
Similar articles
- Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees.
Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, Goudsmit J. Nara PL, et al. J Virol. 1990 Aug;64(8):3779-91. doi: 10.1128/JVI.64.8.3779-3791.1990. J Virol. 1990. PMID: 2370681 Free PMC article. - Human immunodeficiency virus.
Emini EA, Putney SD. Emini EA, et al. Biotechnology. 1992;20:309-26. doi: 10.1016/b978-0-7506-9265-6.50019-1. Biotechnology. 1992. PMID: 1600383 Review. - Antibodies of symptomatic human immunodeficiency virus type 1-infected individuals are directed to the V3 domain of noninfectious and not of infectious virions present in autologous serum.
Schreiber M, Petersen H, Wachsmuth C, Müller H, Hufert FT, Schmitz H. Schreiber M, et al. J Virol. 1994 Jun;68(6):3908-16. doi: 10.1128/JVI.68.6.3908-3916.1994. J Virol. 1994. PMID: 8189527 Free PMC article. - Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
Nara P, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Krone W, Goudsmit J. Nara P, et al. Dev Biol Stand. 1990;72:315-41. Dev Biol Stand. 1990. PMID: 2282990
Cited by
- Complement contributes to antibody-mediated protection against repeated SHIV challenge.
Goldberg BS, Spencer DA, Pandey S, Ordonez T, Barnette P, Yu Y, Gao L, Dufloo J, Bruel T, Schwartz O, Ackerman ME, Hessell AJ. Goldberg BS, et al. Proc Natl Acad Sci U S A. 2023 May 16;120(20):e2221247120. doi: 10.1073/pnas.2221247120. Epub 2023 May 8. Proc Natl Acad Sci U S A. 2023. PMID: 37155897 Free PMC article. - CD4 binding site immunogens elicit heterologous anti-HIV-1 neutralizing antibodies in transgenic and wild-type animals.
Gristick HB, Hartweger H, Loewe M, van Schooten J, Ramos V, Oliveira TY, Nishimura Y, Koranda NS, Wall A, Yao KH, Poston D, Gazumyan A, Wiatr M, Horning M, Keeffe JR, Hoffmann MAG, Yang Z, Abernathy ME, Dam KA, Gao H, Gnanapragasam PNP, Kakutani LM, Pavlovitch-Bedzyk AJ, Seaman MS, Howarth M, McGuire AT, Stamatatos L, Martin MA, West AP Jr, Nussenzweig MC, Bjorkman PJ. Gristick HB, et al. Sci Immunol. 2023 Feb 17;8(80):eade6364. doi: 10.1126/sciimmunol.ade6364. Epub 2023 Feb 10. Sci Immunol. 2023. PMID: 36763635 Free PMC article. - Sequential immunization of macaques elicits heterologous neutralizing antibodies targeting the V3-glycan patch of HIV-1 Env.
Escolano A, Gristick HB, Gautam R, DeLaitsch AT, Abernathy ME, Yang Z, Wang H, Hoffmann MAG, Nishimura Y, Wang Z, Koranda N, Kakutani LM, Gao H, Gnanapragasam PNP, Raina H, Gazumyan A, Cipolla M, Oliveira TY, Ramos V, Irvine DJ, Silva M, West AP Jr, Keeffe JR, Barnes CO, Seaman MS, Nussenzweig MC, Martin MA, Bjorkman PJ. Escolano A, et al. Sci Transl Med. 2021 Nov 24;13(621):eabk1533. doi: 10.1126/scitranslmed.abk1533. Epub 2021 Nov 24. Sci Transl Med. 2021. PMID: 34818054 Free PMC article. - A broadly neutralizing macaque monoclonal antibody against the HIV-1 V3-Glycan patch.
Wang Z, Barnes CO, Gautam R, Cetrulo Lorenzi JC, Mayer CT, Oliveira TY, Ramos V, Cipolla M, Gordon KM, Gristick HB, West AP, Nishimura Y, Raina H, Seaman MS, Gazumyan A, Martin M, Bjorkman PJ, Nussenzweig MC, Escolano A. Wang Z, et al. Elife. 2020 Oct 21;9:e61991. doi: 10.7554/eLife.61991. Elife. 2020. PMID: 33084569 Free PMC article. - Pharmaceutical Approaches to HIV Treatment and Prevention.
Yavuz B, Morgan JL, Showalter L, Horng KR, Dandekar S, Herrera C, LiWang P, Kaplan DL. Yavuz B, et al. Adv Ther (Weinh). 2018 Oct;1(6):1800054. doi: 10.1002/adtp.201800054. Epub 2018 Jul 29. Adv Ther (Weinh). 2018. PMID: 32775613 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials